Patent ID: 11965875
Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
Field: Measurement (Instruments)
Classification: CPC G | IPC C  G

Claim 7:
8. The method according to claim 6, wherein the step b) comprises: assessing the effect of the analyte on the phenotype of T cells, assessing the effect of the analyte on the phenotype of dendritic cells, assessing the effect of the analyte on the phenotype of macrophages, and/or assessing the effect of the analyte on the phenotype of NK cells;
wherein the phenotype of T cells comprises: the expression level of cytokine IL-2 in the T cell, the expression level of IFNγ in the T cell, and/or the proliferative capacity of the T cell;
wherein the phenotype of dendritic cells comprises: the proliferative capacity and the activity of the dendritic cells, the expression levels of the co-stimulatory molecules CD80 and CD86 in the dendritic cells, and the expression level of IL-12 in the dendritic cells, the expression level of type I interferon in the dendritic cells, and/or the expression level of IL-6 in the dendritic cells;
wherein the phenotype of NK cells comprises: the proliferative capacity and the activity of the NK cells, the expression level of NKG2A in the NK cells, the expression level of granzyme in the NK cells, and/or the expression level of KIR in the NK cells; and/or
wherein the phenotype of macrophages comprises: the proliferative capacity and the activity of the macrophages, a ratio of M1-type macrophages to M2-type macrophages, the expression level of co-stimulatory molecules CD80 and CD86 in the macrophages, and/or the expression level of type I interferon produced in the macrophages.